Cilostazol Improves Proangiogenesis Functions in Human Early Endothelial Progenitor Cells through the Stromal Cell-Derived Factor System and Hybrid Therapy Provides a Synergistic Effect In Vivo.

This study investigated the effect of cilostazol on proangiogenesis functions in human early endothelial progenitor cells (EPCs) in vitro and the therapeutic implication of hybrid therapy with cilostazol and human early EPCs in vivo. Cilostazol significantly increased colony-forming units and enhanc...

Descripción completa

Detalles Bibliográficos
Publicado en:BioMed Research International Vol. 2016; pp. 1 - 19
Autores principales: Tseng, Shih-Ya, Chao, Ting-Hsing, Li, Yi-Heng, Cho, Chung-Lung
Formato: pictorial research tables/charts Journal Article
Publicado: Wiley-Blackwell 8/9/2016
Acceso en línea:Ver este registro en EBSCOhost
fields @attributes:
  recordID: 1
pdfLink:
plink: https://search.ebscohost.com/login.aspx?direct=true&db=ccm&AN=117319237&site=ehost-live
header:
  @attributes:
    shortDbName: ccm
    uiTerm: 117319237
    longDbName: CINAHL Complete
    uiTag: AN
  controlInfo:
    bkinfo:
    dissinfo:
    jinfo:
      jid:
        23146133
        FT2T
      jtl: BioMed Research International
      issn: 23146133
      maglogo: N
    pubinfo:
      dt: 8/9/2016
      vid: 2016
      pid: 480
      pub: Wiley-Blackwell
      place: Malden, Massachusetts
    artinfo:
      ui:
        117319237
        117319237
        117319237
        10.1155/2016/3639868
        117319237
      ppf: 1
      ppct: 18
      formats:
        fmt:
          @attributes:
            type: P
      tig:
        atl: Cilostazol Improves Proangiogenesis Functions in Human Early Endothelial Progenitor Cells through the Stromal Cell-Derived Factor System and Hybrid Therapy Provides a Synergistic Effect In Vivo.
      aug:
        au:
          Tseng, Shih-Ya
          Chao, Ting-Hsing
          Li, Yi-Heng
          Cho, Chung-Lung
        affil: Department of Biological Science, National Sun Yat-Sen University, Kaohsiung 704, Taiwan
      sug:
        subj:
          Cilostazol Administration and Dosage
          Neovascularization, Physiologic Drug Effects
          Stem Cells Transplantation
          Chemokines Drug Effects
          Endothelium
          Ischemia Drug Therapy
          Ischemia Therapy
          Cell Therapy
          Combined Modality Therapy
          Human
          Cell Culture Techniques
          In Vivo Studies
          In Vitro Studies
          Cell Migration Assays
          Cell Physiology
          Signal Transduction
          Chemokines Antagonists and Inhibitors
          Protein Kinases
          Biological Assay
          Apoptosis
          Blotting, Western
          Electrophoresis
          Data Analysis Software
          Chemokines Blood
          Flow Cytometry
          Animal Studies
          Mice
          Descriptive Statistics
          T-Tests
          Analysis of Variance
          P-Value
          Vascular Endothelial Growth Factors
          Funding Source
      ab: This study investigated the effect of cilostazol on proangiogenesis functions in human early endothelial progenitor cells (EPCs) in vitro and the therapeutic implication of hybrid therapy with cilostazol and human early EPCs in vivo. Cilostazol significantly increased colony-forming units and enhanced differentiation of EPCs toward endothelial lineage. Treatments resulted in antiapoptotic effects and stimulated proliferation and migration and in vitro vascular tube formation through activation of stromal cell-derived factor-1 (SDF-1)/C-X-C chemokine receptor type 4 (CXCR4)/phosphatidylinositol-3 kinase (PI3K)/Akt signaling pathway. Blood flow recovery and capillary density in murine ischemic hindlimbs were significantly improved in cilostazol-treated, human early EPCs-treated, and cotreatment groups. The effects were attenuated with SDF-1α inhibition. Plasma SDF-1α levels were significantly higher in 3 active treatment groups after surgery, with greatest effects observed in hybrid therapy. The angiogenic effects of transplanted EPCs pretreated with cilostazol ex vivo were superior to untreated EPCs using in vivo Matrigel assay. Implanted EPCs were incorporated into the capillary, with pretreatment or cotreatment with cilostazol resulting in enhanced effects. Taken together, cilostazol promotes a large number of proangiogenic functions in human early EPCs through activation of SDF-1/CXCR4/PI3K/Akt signaling, and hybrid therapy provides a synergistic effect in vivo. Cotreatment may be beneficial in ischemic disease.
      pubtype: Academic Journal
      doctype:
        pictorial
        research
        tables/charts
        Journal Article
      ougenre: Article
    language: English
    refInfo:
    holdings:
      @attributes:
        islocal: N